Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 996,823
  • Shares Outstanding, K 30,061
  • Annual Sales, $ 0 K
  • Annual Income, $ -125,750 K
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.40
Trade RLMD with:

Options Overview Details

View History
  • Implied Volatility 292.02% ( -1.66%)
  • Historical Volatility 64.46%
  • IV Percentile 99%
  • IV Rank 95.66%
  • IV High 302.17% on 09/30/22
  • IV Low 68.56% on 03/03/22
  • Put/Call Vol Ratio 1.48
  • Today's Volume 607
  • Volume Avg (30-Day) 5,164
  • Put/Call OI Ratio 1.57
  • Today's Open Interest 108,889
  • Open Int (30-Day) 66,559

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.40
  • Number of Estimates 4
  • High Estimate -1.16
  • Low Estimate -1.55
  • Prior Year -2.44
  • Growth Rate Est. (year over year) +42.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.65 +22.53%
on 09/22/22
38.68 -9.24%
on 09/30/22
+5.39 (+18.12%)
since 09/02/22
3-Month
18.22 +92.73%
on 07/12/22
38.68 -9.24%
on 09/30/22
+15.86 (+82.37%)
since 07/05/22
52-Week
15.73 +123.11%
on 06/16/22
38.68 -9.24%
on 09/30/22
+9.18 (+35.39%)
since 10/05/21

Most Recent Stories

More News
Chart of the Day: Relmada Therapeutics - Central Nervous System Treatments

The Chart of the Day belongs to the central nervous system treatment company Relmada Therapeutics (RLMD) . I found the stock by sorting Barchart's Bullish Moving Average watchlist by the closest to its...

RLMD : 34.75 (+4.79%)
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 34.75 (+4.79%)
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a late-stage biotechnology company addressing diseases...

RLMD : 34.75 (+4.79%)
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 34.75 (+4.79%)
Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 34.75 (+4.79%)
Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention

/PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today...

RLMD : 34.75 (+4.79%)
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...

SPRC : 0.8800 (-5.38%)
ALKS : 23.02 (+0.04%)
NVS : 77.38 (-1.09%)
RLMD : 34.75 (+4.79%)
JAZZ : 137.11 (-0.94%)
Noteworthy Thursday Option Activity: RLMD, GPMT, CARG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Relmada Therapeutics Inc , where a total volume of 4,005 contracts has been traded...

RLMD : 34.75 (+4.79%)
Notable Tuesday Option Activity: RLMD, ARCH, Y

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Relmada Therapeutics Inc , where a total of 2,580 contracts have traded so far, representing...

RLMD : 34.75 (+4.79%)
Relmada Therapeutics (RLMD) Shares Cross Above 200 DMA

In trading on Thursday, shares of Relmada Therapeutics Inc crossed above their 200 day moving average of $24.03, changing hands as high as $24.17 per share. Relmada Therapeutics Inc shares are currently...

RLMD : 34.75 (+4.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an...

See More

Key Turning Points

3rd Resistance Point 38.28
2nd Resistance Point 37.14
1st Resistance Point 35.15
Last Price 34.75
1st Support Level 32.02
2nd Support Level 30.88
3rd Support Level 28.89

See More

52-Week High 38.68
Last Price 34.75
Fibonacci 61.8% 29.92
Fibonacci 50% 27.21
Fibonacci 38.2% 24.50
52-Week Low 15.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar